MAXCYTE, INC. — fact timeline

MAXCYTE, INC. shareholders approved Ratification of the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“Proposal 2 – Ratification of the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 70,227,193 46,732 30,256”

MAXCYTE, INC. shareholders approved Election of Class II Directors at the 2026-06-17 meeting.

“Proposal 1 – Election of Class II Directors: ​ ​ ​ ​ Nominee For ​ Withhold ​ Broker Non-Votes Patrick Balthrop 39,760,379 ​ 12,728,826 ​ 17,814,976 Cynthia Collins 46,886,614 ​ 5,602,591 ​ 17,814,976 Stanley Erck 40,908,701 ​ 11,580,504 ​ 17,814,976”

MAXCYTE, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5450(a)(1)).

“June 10, 2026, the Company received a letter from Nasdaq, notifying the Company that the staff of Nasdaq has determined that for the last 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of the Company’s common stock has been at $1.00 or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and the matter is now closed. ​ ​ ​ ​ ​ ​ ​ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authoriz”

MAXCYTE, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).

“On May 12, 2026, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”

MAXCYTE, INC. reported full year 2026 results: revenue Expects 2026 revenue of $30-32 million. Guidance initiated.

“Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million”

MAXCYTE, INC. reported fourth quarter ended December 31, 2025 results: revenue total revenue of $7.3 million, net income net loss was $9.6 million.

“Total revenue for the fourth quarter of 2025 was $7.3 million, compared to $8.7 million in the fourth quarter of 2024, representing a decrease of 16%.”

MAXCYTE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“March 16, 2026, MaxCyte, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, and the Company’s common stoc”

MAXCYTE, INC. announced a restructuring with charges of approximately $2.9 million affecting global workforce (approximately 34% of the Company’s workforce globally).

“On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the “Plan”) as part of the Company’s ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities. The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged through third-party employer-of-record (“EOR”) arrangements. ​ In connection with the implementation of the Plan, the Company currently estimates that it will incur an aggregate of approximately $2.9 million of pre-tax, cash charges.”

MAXCYTE, INC. announced a restructuring with charges of approximately $0.8 million affecting global workforce (a reduction of approximately 15% of the Company’s workforce globally).

“engaged through third-party employer-of-record (EOR) arrangements. ​ In connection with the Plan, the Company estimates that it will incur total pre-tax charges of approximately $0.8 million, consisting primarily of severance payments, employee benefits, and related costs. These charges include costs associated with directly employed personnel as well as”

MAXCYTE, INC. reported the quarter ended March 31, 2024 results: revenue $11.3 million, net income $9.5 million. Guidance raised.

“applications, today announced its first quarter ended March 31, 2024 financial results and updated its 2024 guidance. ​ First Quarter Highlights ​ · Total revenue of $11.3 million in the first quarter of 2024, an increase of 32% over the first quarter of 2023. · Core business revenue of $8.2 million in the first quarter of 2024, an increase of 5% over the”

MAXCYTE, INC. reported quarter and year ended December 31, 2023 results: revenue Total revenue of $15.7 million in the fourth quarter of 2023, net income Fourth quarter 2023 net loss was $5.3 million. Guidance reaffirmed.

“MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance”

MAXCYTE, INC. reported fiscal year ended December 31, 2023 results: revenue between $41.1 million and $41.3 million.

“Total revenue for the fiscal year of 2023 is expected to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022.”

Cenk Sumen departed as Chief Scientific Officer at MAXCYTE, INC..

“On January 23, 2024, Cenk Sumen, Ph.D.’s employment as Chief Scientific Officer of MaxCyte, Inc. (the “ Company ”), ended.”

MAXCYTE, INC. reported the fiscal year ended December 31, 2023 results: revenue between $41.1 and $41.3 million.

“Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.”

MAXCYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $15.5 million and $15.7 million.

“Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.”

Maher Masoud was appointed as President and Chief Executive Officer at MAXCYTE, INC..

“On December 10, 2023, the Board appointed Maher Masoud, currently the Company’s Executive Vice President, General Couns...”

Doug Doerfler retired as President, Chief Executive Officer and Director at MAXCYTE, INC..

“On December 10, 2023, Doug Doerfler, President and Chief Executive Officer of MaxCyte, Inc. (the “ Company ”), notified the Company’s Board of Directors (the “ Board ”) of his decision to retire from those positions and as a member of the Board, in each case effective as of December 31, 2023 (the “ Retirement Date ”).”

MAXCYTE, INC. reported the third quarter ended September 30, 2023 results: revenue Total revenue of $8.0 million in the third quarter of 2023, net income Third quarter 2023 net loss was $11.3 million. Guidance reaffirmed.

“MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications , today announced financial results for the third quarter ended September 30, 2023.”

MAXCYTE, INC. reported the quarter ended September 30, 2023 results: revenue $7.8 – 8.0 million. Guidance reaffirmed.

“preliminary revenue for the third quarter ended September 30, 2023 and updated its full year 2023 revenue guidance. ​ Preliminary Third Quarter 2023 Revenue · Total revenue of $7.8 – 8.0 million in the third quarter of 2023, a decrease of 25 -27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector. ·”

MAXCYTE, INC. reported the six months ended June 30, 2023 results: revenue $17.6 million, net income $21.4 million. Guidance reaffirmed.

“Total revenue for the first half of 2023 was $17.6 million, compared to $21.2 million in the first half of 2022, representing a decline of 17%.”

MAXCYTE, INC. reported the quarter ended June 30, 2023 results: revenue $9.0 million, net income $10.5 million. Guidance reaffirmed.

“Total revenue for the second quarter of 2023 was $9.0 million, compared to $9.6 million in the second quarter of 2022, representing a decline of 6%.”

MAXCYTE, INC. shareholders approved Ratification of the appointment of CohnReznick LLP as independent registered public accounting firm at the 2023-06-22 meeting.

“Proposal No. 3: Ratification of the appointment of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of CohnReznick LLP 83,086,872 5,981 136,621”

MAXCYTE, INC. shareholders approved Approval of the Amended 2022 Plan at the 2023-06-22 meeting.

“Proposal No. 2: Approval of the Amended 2022 Plan. The votes were cast as follows: Votes For Votes Against Abstained Approval of an amendment and restatement of the 2022 Equity Incentive Plan 67,398,179 9,101,146 217,247 Broker Non-Votes: 6,512,902”

MAXCYTE, INC. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting at the 2023-06-22 meeting.

“Proposal No. 1: Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Art Mandell 43,059,349 33,657,223 Stanley C. Erck 45,186,194 31,530,378 Patrick J. Balthrop 76,115,643 600,929 Broker Non-Votes: 6,512,902 All nominees were elected.”

MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.

“Total revenue for the first quarter of 2023 was $8.6 million, compared to $11.6 million in the first quarter of 2022, representing a decline of 26%.”

Ron Holtz changed role as EVP, Administration at MAXCYTE, INC..

“Ron Holtz, who had served as the Company’s interim Chief Financial Officer since April 15, 2022, will continue as the Company’s EVP, Administration.”

Douglas J. Swirsky was appointed as Chief Financial Officer at MAXCYTE, INC..

“On March 27, 2023, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Douglas J. Swirsky as the Company’s Chief Financial Officer, effective immediately.”

MAXCYTE, INC. updated its the quarter and year ended December 31, 2022 guidance (initiated).

“On March 15, 2023, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

Patrick J. Balthrop, Sr. was appointed as Class II director at MAXCYTE, INC..

“On November 30, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “ Nominating Committee ”), the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Patrick J. Balthrop, Sr. to serve as a Class II director.”

MAXCYTE, INC. reported financial results for the nine months ended September 30, 2022.

“announcing its financial results for the quarter and nine months ended September 30, 2022”

MAXCYTE, INC. reported the third quarter ended September 30, 2022 results: revenue $10.6 million, net income $6.4 million. Guidance reaffirmed.

“Total revenue of $10.6 million in the third quarter of 2022”

Ron Holtz was appointed as Interim Chief Financial Officer at MAXCYTE, INC..

“On April 8, 2022, the Board of Directors of the Company appointed Ron Holtz, currently the Company’s Senior Vice President and Chief Accounting Officer, as Interim Chief Financial Officer, effective upon Ms. Murphy’s departure.”

Amanda L. Murphy resigned as Chief Financial Officer at MAXCYTE, INC..

“On April 7, 2022, Amanda L. Murphy, Chief Financial Officer of the Company, resigned from that position, effective as of April 15, 2022, to pursue other interests.”

J. Stark Thompson departed as Chairman of the Board and Director at MAXCYTE, INC..

“On September 30, 2021, Dr. J. Stark Thompson notified the board of directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) that he will not stand for re-election at the Annual Meeting of Stockholders to be held on October 29, 2021 (the “ Annual Meeting ”).”